 |
 |
Laura Liget wrote >You are similarly out of luck if you need a decongestant or antihistamine. >Luckily I have found one cough syrup and one antihistamine I can take. (My PD >meds are Sinemet, Eldepryl, Requip, Tasmar & Nortryptiline.) The cough syrup >is Naldecon Senior DX (Guaifenesin & Dextromethorphan hydrobromide) and Carol Mcleod: > >Keith , there is an alternative to cough syrups called Guaifenesin , It >it a pill and you need a prescription for it . >I use it , it thins out mucus so it can be drained out . I was told >there is no interaction with other drugs and >I have experienced none so far myself . I also use Zyrtec for allergy >(prescription) and it has worked well with >no P.D. drug interaction . and Athur Hirsch: >Here is my understanding: there are two types of mono-amine oxidase >inhibitors (MOA-I), type A and type B. Type A interacts with the >medications in the patent medicines such as Day-Quil and Sudafed. Type B >does not. >Eldepryl (Selegiline) is a selective MOA-I, type B only, when taken in >small quantities. Ten mg per day is considered a small quantity. In >larger quantities, it loses its selective property and becomes both A and >B. Therefore, it may become dangerous, so the warning is necessary. Listmembers, In Holland one does not need a prescription to buy a cough syrop or pills wich has the same ingredient as Guaifenesin viz, dextrometorphan, which is a glutamate antagonist.The leaflet with the instructions for use, says however it should not te be used in combination with a MAO inhibitor. Dextrometorphan has replaced codeine, which did lead to abuse. Some searching in usenet alt. drugs learned me that among for-fun-drug-users dextrometophan is known. Warning is indeed necessary. In higher doses it is certainly not harmless, so this is not to advise to start using it. But I think the whole attention for anti-glutamates is interesting, because if it leads to a regular med against PD, it will attack PD in a rather different way as dopamine does or dopamine agonists or meds who inhibit the deconstruction of dopamine In Holland one does not need a prescription to buy a cough syrop or pills wich has the same ingredient as Guaifenesin viz, dextrometorphan, which is a glutamate antagonist.The leaflet with the instructions for use, says however it should not te be used in combination with a MAO inhibitor. I wrote recently something about the importance that anti-glutamates might have for PWP's.The summary of an article from CNS drugs from aptil 1998 is added to this mail for people who are interested in more background An old medicine for PD, which recently was mentioned to be have a pos. effect on dopamine-induced dyskinesia, amantadine, has that effect because it is(next to an anti virus med)an antiglutamate, though a weak one. I have done some additional searching on the net and learned that researchers of the university of Tuebingen (Germany) did already develope another anti-glutamate Memantine, which is so they expect effective as an anti-parkinson med. and an anti-craving med for alcohol-- and other addictivs. People who are interested, might look around themselves on the site of Tuebingen <bigger>They have most of their texts in German and in English. http://www.uni-tuebingen.de/uni/bzn/index-e.html </bigger> CNS drugs juni 1998 Summary GLUTAMATE ANTAGONISTS FOR PARKINSON'S DISEASE Rationale for Use and Therapeutic Implications Alison J Cooper,Camille B Carrol and Ian J. Mitchell. Parkinson's disease results from degeneration of dopaminergic neurons within the substantia nigra. The treatment of the disease was revolutionised by the introduction of dopamine replacement tharapy. However, it has become increasingly clear that prolonged administration of dopamine agonists results in the onset of a spectrum serious adversive effects, including dyskinesias. Accordingly, there is great interest in alternative strategies for the treatment of this condition. It is now realised that the loss of nigral dopamine cells and subsequent lowering of striatal dopamine levels causes a chain of pathofysiological events within the basal ganglia. One of the most prominent of these events is an elevation in the level of glutamate-mediated transmission within the striatum and the output structures of the the basal ganglia. A range of glutamate antagonists has been shown to alleviate symptoms in animal models of Parkinson's disease. Antagonists of both the N-methyl-D-aspertate (NMDA) and the a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPDA) subtypes of the glutamate receptor result in an improvement in motor behaviour on experimental animal models. However, systematic administration of NMDA antagonists is also associated with several adverse effects, the most common being ataxia, sedation and cognitive impairments. These problems can potentially be overcome by the use of antagonists that are selective for the subtypes of NMDA receptors, which are preferentially expressed in the critical parts of the pathophysiological circuitry. Glutmate antagonists are also known to have strong neuroprotective effects. Consequently, administration of glutamate antagonists may slow the loss od nigral dopaminergic neurons and thus slow the progression of Parkinson's disease Regards Ida -------------------------------------------------------------- Vriendelijke Groeten / Kind regards, Ida Kamphuis mailto: [log in to unmask]